Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | GPR183 | P32249 | 1/20 | 0.60 |
| ▸ | GHSR | Q92847 | 2/20 | 0.54 |
| ▸ | FASN | P49327 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | NUDT15 | Q9NV35 | 1/20 | 0.51 |
| ▸ | OXTR | P30559 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30066210 | 1.00 | MAPK14 (0.62) | MAPK14GPR183GHSRFASNKDR | |
| SCHEMBL3235960 | 0.90 | GHSR (0.67) | MAPK14GPR183GHSRHRH4HRH3 | |
| SCHEMBL29990457 | 0.90 | GHSR (0.67) | MAPK14GPR183GHSRHRH4HRH3 | |
| SCHEMBL31435010 | 0.89 | MAPK14 (0.59) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL8534513 | 0.88 | MAPK14 (0.64) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL30226931 | 0.88 | MAPK14 (0.64) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL22216445 | 0.88 | MAPK14 (0.64) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL30329646 | 0.88 | MAPK14 (0.64) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL2214616 | 0.87 | MAPK14 (0.63) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL3457123 | 0.87 | MAPK14 (0.63) | MAPK14GPR183GHSRFASNDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-2029534-B1 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| CN-101605757-A | Be used for (indoles-4-yl) of obesity treatment-or (indoles-5-yl)-piperazinyl methanone derivatives | HOFFMANN LA ROCHE (CH) | 2009-12-16 | — | — | CN | disclosed |
| CN-101605757-A | Be used for (indoles-4-yl) of obesity treatment-or (indoles-5-yl)-piperazinyl methanone derivatives | HOFFMANN LA ROCHE (CH) | 2009-12-16 | — | — | CN | disclosed |
| EP-2118057-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| CN-101443311-A | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | CN | disclosed |
| EP-2029534-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-7432255-B2 | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432255-B2 | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2008095820-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007131907-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HRH4, HRH2, HRH3 | MAPK14 3279/4885GPR183 168/4885GHSR 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.